Biotin supplement lawsuits have primarily centered on deceptive marketing claims rather than the supplement’s actual effectiveness, though a more serious FDA safety concern has emerged regarding laboratory test interference. The most notable case, Greenberg v. Target Corporation, was dismissed in 2021 when a federal court ruled that the plaintiff’s state law claims were preempted by federal law allowing dietary supplements to make structure/function claims. Similarly, a major case against NBTY Inc. and Nature’s Bounty Inc.
over misleading biotin marketing ended when the plaintiff voluntarily dropped her appeal and dismissed her claims. These legal outcomes mean that consumers who believed they were misled about biotin’s effects on hair and skin have had limited recourse through the court system. However, the more pressing issue is not whether biotin works as advertised, but whether high-dose supplements are safe. The FDA has documented serious health risks from biotin supplements, including at least one documented death caused by biotin’s interference with lab test results. This interference occurs because many dietary supplements contain biotin at levels up to 650 times the recommended daily intake, with some products delivering as much as 10 milligrams of biotin per serving. The FDA issued safety communications in November 2017 and again in November 2019 warning healthcare providers and patients about this laboratory test interference risk, making this the most significant legal and health issue surrounding biotin supplements.
Table of Contents
- What Are the Major Biotin Supplement Court Cases?
- The FDA Safety Concern That Changed Everything
- How Does Biotin Interfere with Laboratory Tests?
- What Are the Legal Options for Biotin-Related Injuries?
- Why Haven’t More Class Actions Been Filed?
- What Should Consumers Know About High-Dose Biotin?
- Looking Forward: Regulatory Changes and Manufacturer Responsibility
- Conclusion
- Frequently Asked Questions
What Are the Major Biotin Supplement Court Cases?
The litigation landscape around biotin supplements is largely defined by plaintiff defeats and case dismissals. In Greenberg v. Target Corporation, decided by the Ninth Circuit Court of Appeals in January 2021, a consumer challenged Target’s Up & Up brand biotin supplements for claiming to “help support healthy hair and skin.” The plaintiff argued these claims were deceptive and violated state consumer protection laws. However, the court dismissed the case on preemption grounds, ruling that the federal Dietary Supplement Health and Education Act (DSHEA) specifically permits dietary supplement manufacturers to make structure/function claims—claims that describe how a nutrient or dietary ingredient affects normal structure or function of the body. This meant that even if Target’s claims were unproven, they were legally permissible under federal law, leaving the plaintiff without a viable legal theory.
Similarly, a case against NBTY Inc. and Nature’s Bounty Inc., major manufacturers of biotin supplements, saw the plaintiff voluntarily dismiss her appeal and drop her deceptive marketing claims. This withdrawal eliminated one of the few pending cases challenging biotin marketing directly. These dismissals reflect a broader legal reality: as long as supplement manufacturers stick to structure/function claims rather than disease claims, they have significant legal protection under federal law, regardless of whether the claims are scientifically validated. This has left disappointed consumers with limited options for legal recovery when biotin supplements fail to produce the promised benefits for hair, skin, or nails.
The FDA Safety Concern That Changed Everything
While the marketing lawsuits failed, a far more serious safety issue emerged that has reshaped the regulatory and medical landscape around biotin supplements. In November 2017, the FDA issued a Safety Communication warning that biotin may interfere with certain laboratory tests, potentially leading to inaccurate results. The agency updated this warning in November 2019 with additional information about the scope and severity of the problem. The interference occurs because biotin—also known as vitamin B7—is used in certain immunoassay tests to measure important health markers like troponin (a cardiac biomarker), thyroid hormone levels, and hormone levels in pregnancy tests. The consequences of this interference have proven fatal.
The FDA documented at least one death caused by false test results when a patient taking high-dose biotin supplements received a falsely low troponin test result. Because the test made it appear the patient’s heart was healthy when it was not, appropriate treatment was delayed or not provided, resulting in the patient’s death. This case exemplifies why biotin interference is not a theoretical concern but a genuine threat to patient safety. The danger is compounded by the fact that many over-the-counter biotin supplements contain levels of biotin up to 650 times higher than the recommended daily intake, with some formulations delivering up to 10 milligrams of biotin. Consumers taking these products for cosmetic reasons—healthier hair and skin—may have no idea they are inadvertently compromising the accuracy of their medical tests.
How Does Biotin Interfere with Laboratory Tests?
Biotin’s interference with lab tests occurs through a mechanism specific to certain testing methods. Many clinical laboratories use streptavidin-biotin technology in immunoassays—tests that measure specific substances in blood samples by using biotin-labeled reagents. When a patient has extremely high levels of biotin in their bloodstream from supplements, the excess biotin can directly interfere with these assays, causing falsely low or falsely high results depending on the test. The most critical concern involves cardiac troponin testing, which is essential for diagnosing heart attacks. If a troponin test gives a falsely low result because of biotin interference, physicians may incorrectly conclude that a patient is not having a heart attack, leading to delayed or withheld treatment.
Other tests vulnerable to biotin interference include thyroid function tests (TSH, free T4), parathyroid hormone (PTH) tests, pregnancy tests, and various tumor marker assays. The FDA’s safety communications specifically highlighted these vulnerable test categories. Notably, some laboratory tests are more susceptible to biotin interference than others, and not all labs use the same testing platforms. A patient taking high-dose biotin might receive accurate results at one hospital but inaccurate results at another facility using a different testing method. This unpredictability creates a serious blind spot: patients and even their physicians may not realize that a test result is compromised by supplement use.
What Are the Legal Options for Biotin-Related Injuries?
Given the dismissal of the major deceptive marketing cases, consumers injured by biotin interference or by biotin supplements do not have straightforward class action remedies available. However, there are other potential legal avenues. A person who suffered harm from biotin interference with lab tests might pursue a personal injury claim against the supplement manufacturer if they can establish that the manufacturer failed to adequately warn about the risk of laboratory test interference. The argument would be that the manufacturer knew or should have known about the FDA’s 2017 safety warning, and yet failed to place prominent warnings on the supplement’s label or packaging alerting consumers to the test interference risk.
Additionally, some injured patients might have claims against healthcare providers or laboratories if they failed to ask about biotin or other supplements during pre-test screening, or if they used testing methods known to be vulnerable to biotin interference without taking appropriate precautions. The landscape is complicated because it requires proving that the specific harm was caused by biotin interference and that the defendant had a duty to prevent that harm. The 2017 and 2019 FDA safety communications established that biotin interference was a known risk, which could support arguments that manufacturers and healthcare providers should have taken preventive measures. However, establishing causation and liability remains difficult in individual cases.
Why Haven’t More Class Actions Been Filed?
The lack of successful biotin supplement litigation reflects several legal and practical obstacles. First, as demonstrated in Greenberg v. Target, federal law explicitly permits structure/function claims for dietary supplements, which severely limits the basis for deceptive advertising claims. A manufacturer can claim that biotin supports hair and skin health without providing rigorous clinical evidence, and this is legal. Second, proving economic injury in a biotin case is difficult.
Unlike a defective product that fails to function at all, or a food contaminated with harmful bacteria, biotin supplements do contain biotin and may provide some benefit to some consumers. The injury is not that the product is fake, but that it may not work as well as promised, and such cosmetic disappointment has been difficult to frame as a legal injury. Third, and most significantly, the death and adverse events documented by the FDA represent rare outcomes that are difficult to link to any particular manufacturer. The documented fatality involved biotin interference with lab tests, not inherent toxicity of biotin itself. This creates a causation problem: even if a person can prove they took biotin supplements and suffered test interference, proving that this particular manufacturer’s product caused their injury requires medical and scientific evidence that may be difficult and expensive to obtain. Furthermore, by the time consumers realize they were harmed by biotin interference, the relevant test results and medical records must be obtained and analyzed, which creates evidence and cost barriers to litigation.
What Should Consumers Know About High-Dose Biotin?
The FDA’s safety warnings make clear that consumers using high-dose biotin supplements face real risks, particularly if they have conditions requiring regular blood tests. The recommended daily intake of biotin is 30 micrograms, but many over-the-counter supplements contain 1,000 to 10,000 micrograms (1 to 10 milligrams), meaning they provide 30 to 300 times the recommended amount. Some formulations go even higher, delivering up to 650 times the recommended daily amount. Before taking biotin supplements, consumers should inform their healthcare providers, especially if they have heart conditions, thyroid disease, or are pregnant.
This allows physicians to choose testing methods that are less vulnerable to biotin interference or to adjust testing schedules to allow time for biotin to clear from the system. Additionally, consumers should be aware that stopping biotin supplements before a lab test does not immediately eliminate the interference risk. Biotin is water-soluble and typically clears from the body within 24 to 48 hours of stopping supplementation, but timing can vary. Many medical organizations, including the American Society of Anesthesiologists, have issued guidance recommending that patients discontinue biotin supplements at least 72 hours before laboratory testing when possible. However, this guidance is not universally followed, and many patients do not remember to mention their supplement use to their healthcare providers.
Looking Forward: Regulatory Changes and Manufacturer Responsibility
The FDA’s safety communications have prompted some regulatory movement, but comprehensive labeling requirements for biotin supplements have not yet been implemented as of 2026. Some manufacturers have voluntarily added warnings about laboratory test interference to their products, but there is no mandate requiring all biotin supplement manufacturers to do so. The FDA has indicated that it is considering further regulatory action to address biotin’s lab test interference risk, and there is ongoing discussion within the medical and regulatory communities about whether stronger measures are needed.
Some proposals include requiring prominent, standardized warnings on all high-dose biotin supplements, or establishing maximum allowable biotin levels in over-the-counter supplements. The biotin supplement situation illustrates a broader challenge in the dietary supplement industry: federal law gives manufacturers significant flexibility in making marketing claims and designing products, while the practical and medical consequences of supplement use can be serious. As long as deceptive advertising claims remain protected by federal preemption law, the primary recourse for injured consumers may lie in FDA regulatory action or in personal injury lawsuits against manufacturers that fail to warn about known risks. The documented death caused by biotin interference with lab tests provides a cautionary example of why these warnings matter.
Conclusion
Biotin supplement lawsuits have not resulted in major class action victories for consumers disappointed with the supplement’s cosmetic effects, as federal law permits manufacturers to make structure/function claims for dietary supplements without rigorous clinical proof. The Greenberg v. Target case and the NBTY dismissal established that state law deceptive advertising claims are preempted by federal dietary supplement law. However, the more significant issue is not whether biotin fulfills its marketing promises, but whether high-dose supplements are safe.
The FDA documented at least one death caused by biotin’s interference with laboratory test results, and many commercial biotin supplements contain doses 650 times higher than the recommended daily intake. Consumers considering biotin supplements should inform their healthcare providers and be aware of the test interference risk, particularly before undergoing cardiac or hormonal testing. The legal landscape may evolve if the FDA implements stronger labeling requirements or if injured patients successfully pursue personal injury claims against manufacturers that fail to warn about the known laboratory test interference risk. For now, the most important protection is awareness and communication between patients and their healthcare providers about supplement use.
Frequently Asked Questions
Can I sue a biotin supplement manufacturer for false advertising?
It is difficult to succeed in a deceptive advertising lawsuit against a biotin supplement manufacturer because federal law permits structure/function claims for dietary supplements. This legal protection applies as long as manufacturers do not make disease claims (e.g., “cures alopecia”). Recent cases like Greenberg v. Target were dismissed on preemption grounds.
What is biotin interference and why does it matter?
Biotin interference occurs when high levels of biotin from supplements interfere with certain laboratory tests that use streptavidin-biotin technology, potentially producing inaccurate results. This is particularly dangerous for cardiac troponin tests, which diagnose heart attacks. The FDA documented at least one death from false lab results caused by biotin interference.
Should I stop taking biotin supplements?
This is a decision to make with your healthcare provider. If you take biotin supplements, you should inform your doctor, especially before any blood tests. You may be advised to discontinue biotin at least 72 hours before certain tests. The risk is primarily related to laboratory test interference, not biotin toxicity itself.
How much biotin is too much?
The recommended daily intake of biotin is 30 micrograms. Many over-the-counter supplements contain 1,000 to 10,000 micrograms, and some contain even higher amounts. The FDA has not established a maximum safe level, but has warned about interference risks from high-dose supplements.
Will there be a class action settlement for biotin supplement injuries?
As of 2026, there is no major pending class action settlement related to biotin supplements. The major cases have been dismissed on legal grounds. Injured patients may pursue individual personal injury claims if they can establish that a manufacturer failed to warn about test interference risks.
What tests are most affected by biotin?
Tests most vulnerable to biotin interference include cardiac troponin tests, thyroid function tests (TSH, free T4), parathyroid hormone tests, pregnancy tests, and various hormone and tumor marker assays. Not all laboratories are equally affected because different facilities use different testing methods.